JP5497372B2 - 非ステロイド性抗炎症薬起因性潰瘍の予防・治療薬 - Google Patents
非ステロイド性抗炎症薬起因性潰瘍の予防・治療薬 Download PDFInfo
- Publication number
- JP5497372B2 JP5497372B2 JP2009190086A JP2009190086A JP5497372B2 JP 5497372 B2 JP5497372 B2 JP 5497372B2 JP 2009190086 A JP2009190086 A JP 2009190086A JP 2009190086 A JP2009190086 A JP 2009190086A JP 5497372 B2 JP5497372 B2 JP 5497372B2
- Authority
- JP
- Japan
- Prior art keywords
- astaxanthin
- teprenone
- nsaids
- ulcers
- steroidal anti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 title claims description 34
- 208000025865 Ulcer Diseases 0.000 title claims description 29
- 231100000397 ulcer Toxicity 0.000 title claims description 29
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 title claims description 5
- 235000013793 astaxanthin Nutrition 0.000 claims description 51
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 50
- 229940022405 astaxanthin Drugs 0.000 claims description 50
- 239000001168 astaxanthin Substances 0.000 claims description 50
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 40
- DJAHKBBSJCDSOZ-AJLBTXRUSA-N (5z,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one;(5e,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C/CCC(C)=O.CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O DJAHKBBSJCDSOZ-AJLBTXRUSA-N 0.000 claims description 26
- 229950006156 teprenone Drugs 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 19
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 16
- 239000000194 fatty acid Substances 0.000 claims description 16
- 229930195729 fatty acid Natural products 0.000 claims description 16
- 229940124597 therapeutic agent Drugs 0.000 claims description 14
- -1 astaxanthin fatty acid esters Chemical class 0.000 claims description 12
- 230000000069 prophylactic effect Effects 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 241000168525 Haematococcus Species 0.000 claims description 6
- 230000000694 effects Effects 0.000 description 10
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 10
- 208000007107 Stomach Ulcer Diseases 0.000 description 9
- 201000005917 gastric ulcer Diseases 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 5
- 229960000905 indomethacin Drugs 0.000 description 5
- 208000018522 Gastrointestinal disease Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000000035 biogenic effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013176 antiplatelet therapy Methods 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000001924 fatty-acyl group Chemical group 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000013970 phaffia yeast Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
[1]アスタキサンチン及びアスタキサンチン脂肪酸エステルの混合物とテプレノンとを含む、NSAIDs起因性潰瘍の予防・治療薬。
[2]アスタキサンチン及びアスタキサンチン脂肪酸エステルの混合物がヘマトコッカス藻由来である、請求項1記載の予防・治療薬。
[3]アスタキサンチンとテプレノンとを含む、NSAIDs起因性潰瘍の予防・治療薬。
[4]アスタキサンチン脂肪酸エステルとテプレノンとを含む、NSAIDs起因性潰瘍の予防・治療薬。
Claims (4)
- アスタキサンチン及びアスタキサンチン脂肪酸エステルの混合物とテプレノンとを含む、非ステロイド性抗炎症薬起因性潰瘍の予防・治療薬。
- アスタキサンチン及びアスタキサンチン脂肪酸エステルの混合物がヘマトコッカス藻由来である、請求項1記載の予防・治療薬。
- アスタキサンチンとテプレノンとを含む、非ステロイド性抗炎症薬起因性潰瘍の予防・治療薬。
- アスタキサンチン脂肪酸エステルとテプレノンとを含む、非ステロイド性抗炎症薬起因性潰瘍の予防・治療薬。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009190086A JP5497372B2 (ja) | 2009-08-19 | 2009-08-19 | 非ステロイド性抗炎症薬起因性潰瘍の予防・治療薬 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009190086A JP5497372B2 (ja) | 2009-08-19 | 2009-08-19 | 非ステロイド性抗炎症薬起因性潰瘍の予防・治療薬 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011042590A JP2011042590A (ja) | 2011-03-03 |
JP5497372B2 true JP5497372B2 (ja) | 2014-05-21 |
Family
ID=43830295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009190086A Expired - Fee Related JP5497372B2 (ja) | 2009-08-19 | 2009-08-19 | 非ステロイド性抗炎症薬起因性潰瘍の予防・治療薬 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5497372B2 (ja) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09124470A (ja) * | 1995-10-26 | 1997-05-13 | Suntory Ltd | 抗ストレス組成物 |
SE522246C2 (sv) * | 1997-02-27 | 2004-01-27 | Astacarotene Ab | Oralt preparat för profylaktisk och terapeutisk behandling av Helicobacter Sp. infektion |
US7087649B2 (en) * | 2001-06-07 | 2006-08-08 | Eisai Co., Ltd. | Methods for preventing and treating diseases and conditions associated with cellular stress |
WO2009093595A1 (ja) * | 2008-01-25 | 2009-07-30 | Fujifilm Corporation | カロテノイド含有エマルション組成物の製造方法、それにより得られるカロテノイド含有エマルション組成物並びにカロテノイド含有粉末組成物、該組成物を含む機能性食品及び化粧品 |
-
2009
- 2009-08-19 JP JP2009190086A patent/JP5497372B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2011042590A (ja) | 2011-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2493478B1 (en) | Concentrated therapeutic phospholipid compositions | |
JP2023002662A5 (ja) | ||
EP1861169B1 (en) | Use of 13,14-dihydro-15-keto-16,16-difluoro prostaglandin E1 or 13,14-dihydro-15-keto-16,16-difluoro-18-methyl prostaglandin E1 for the treatment of cancer | |
CN101198334B (zh) | 前列腺素化合物和质子泵抑制剂用于治疗肠胃病的联合应用 | |
EP2175861B1 (en) | Pharmaceutical combination of naproxen with 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E1 | |
US8202909B2 (en) | Method for treating central nervous system disorders | |
IL239893A (en) | Preparations including 15-ohepa and methods of use | |
Capasso et al. | Preventive effect of eugenol on PAF and ethanol-induced gastric mucosal damage | |
RU2013108944A (ru) | Ингибиторы faah периферически-ограниченного действия | |
AU2007341218B2 (en) | Isosorbide mononitrate derivatives for the treatment of intestinal disorders | |
WO2021190647A1 (zh) | 小檗碱类似物与jak抑制剂在胃肠道炎症性疾病治疗中的用途 | |
ES2443390T3 (es) | Agente preventivo/terapéutico para la demencia de tipo Alzheimer | |
CA3055464A1 (en) | Acefapc for the treatment of acetylcholine-dependent diseases | |
JP5497372B2 (ja) | 非ステロイド性抗炎症薬起因性潰瘍の予防・治療薬 | |
JP2013216679A (ja) | 非アルコール性脂肪性肝炎の予防及び/又は治療のための医薬 | |
AU2013202114A1 (en) | Acne treatment | |
KR101329575B1 (ko) | 구굴스테론 유도체를 유효성분으로 포함하는 위점막 보호용 약학 조성물 | |
JP7508447B2 (ja) | 血糖制御を改善し、炎症性腸疾患を処置するための構造修飾脂肪酸 | |
TW201116277A (en) | Pharmaceutical combination for treating tumor | |
JP2008533186A (ja) | 腸炎治療のためのマクロライド類の使用 | |
Sontag | Prostaglandins and Acid Peptic Disease. | |
AU2018315094A1 (en) | Methods and compositions for treatment of inflammatory bowel disease | |
Tyagi et al. | Treatment of peptic ulcer; current status and potential strategies | |
Liang et al. | A clinical analysis of nutritional therapy in 157 cases with advanced malignancy | |
EP2184284A1 (en) | Preventive, inhibitor or remedy for cerebral aneurysm comprising ibudilast as the active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120619 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131015 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140304 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140306 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5497372 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |